# Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma

> **NIH NIH P01** · DANA-FARBER CANCER INST · 2020 · $186,148

## Abstract

Project Summary (Project 1)
To improve overall outcome in multiple myeloma (MM), in the current funding period this project
achieved two major goals: 1: Defined the role of transplant in the era of novel agents –establishing
integration of transplant with novel agents as the standard of care for newly-diagnosed patients 2:
Redefined Complete Remission, establishing the feasibility of measuring minimal residual disease
(MRD) using sequencing-based method and its significant impact on prolongation of PFS. In this
renewal application, we now propose to build upon our highly successful collaborative clinical study to
address the next most important question, whether less intense maintenance (1-drug) provides
adequate benefit compared to more intense maintenance (2-drug) and whether MRD negative status
should be the ultimate goal. We hypothesize that achieving MRD negative status will lead to long-
term disease free survival, and that irrespective of how one gets to MRD negative status, the overall
outcome will be similar. To achieve these goals, in Specific Aim 1 we will perform a large 1,260
patient study utilizing lenalidomide, ixazomib, and dexamethasone with daratumumab (RID-Dara) as
induction and consolidation post high-dose therapy. Those not achieving MRD negative status will
receive 2nd HDT. All MRD negative patients will be randomized to lenalidomide versus lenalidomide
plus daratumumab maintenance. The study will also evaluate MRD status at various time points and
investigate whether early versus late MRD status will affect overall outcome. In specific Aim 2, we will
redefine new risk stratification incorporating MRD status and all genomic/epigenomic correlates.

## Key facts

- **NIH application ID:** 9987296
- **Project number:** 5P01CA155258-09
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** herve Avet loiseau
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $186,148
- **Award type:** 5
- **Project period:** 2011-12-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9987296

## Citation

> US National Institutes of Health, RePORTER application 9987296, Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma (5P01CA155258-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9987296. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*